WO2006010499A3 - Diagnostics and therapeutics for diseases associated with carboxypeptidase a2 (cpa2) - Google Patents

Diagnostics and therapeutics for diseases associated with carboxypeptidase a2 (cpa2) Download PDF

Info

Publication number
WO2006010499A3
WO2006010499A3 PCT/EP2005/007708 EP2005007708W WO2006010499A3 WO 2006010499 A3 WO2006010499 A3 WO 2006010499A3 EP 2005007708 W EP2005007708 W EP 2005007708W WO 2006010499 A3 WO2006010499 A3 WO 2006010499A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
cpa2
carboxypeptidase
therapeutics
diagnostics
Prior art date
Application number
PCT/EP2005/007708
Other languages
French (fr)
Other versions
WO2006010499A2 (en
Inventor
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Original Assignee
Bayer Healthcare Ag
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Stefan Golz, Ulf Brueggemeier, Andreas Geerts filed Critical Bayer Healthcare Ag
Publication of WO2006010499A2 publication Critical patent/WO2006010499A2/en
Publication of WO2006010499A3 publication Critical patent/WO2006010499A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention provides a human CPA2 which is associated with the endocrinological diseases, metabolic diseases, inflammation, gastroenterological diseases, cancer, muslce skeleton diseases, reproduction diseases, urological diseases and neurological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of endocrinological diseases, metabolic diseases, inflammation, gastroenterological diseases, cancer, muslce skeleton diseases, reproduction diseases, urological diseases and neurological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of CPA2 as well as pharmaceutical compositions comprising such compounds.
PCT/EP2005/007708 2004-07-28 2005-07-15 Diagnostics and therapeutics for diseases associated with carboxypeptidase a2 (cpa2) WO2006010499A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04017825 2004-07-28
EP04017825.3 2004-07-28

Publications (2)

Publication Number Publication Date
WO2006010499A2 WO2006010499A2 (en) 2006-02-02
WO2006010499A3 true WO2006010499A3 (en) 2006-03-30

Family

ID=34981776

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/007708 WO2006010499A2 (en) 2004-07-28 2005-07-15 Diagnostics and therapeutics for diseases associated with carboxypeptidase a2 (cpa2)

Country Status (1)

Country Link
WO (1) WO2006010499A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998373A (en) * 1997-06-09 1999-12-07 Incyte Pharmaceuticals, Inc. Carboxypeptidase inhibitor
WO2002012331A2 (en) * 2000-08-07 2002-02-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of pancreatic cancer
US20040058338A1 (en) * 2001-12-03 2004-03-25 Agee Michele L. Novel proteins and nucleic acids encoding same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998373A (en) * 1997-06-09 1999-12-07 Incyte Pharmaceuticals, Inc. Carboxypeptidase inhibitor
WO2002012331A2 (en) * 2000-08-07 2002-02-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of pancreatic cancer
US20040058338A1 (en) * 2001-12-03 2004-03-25 Agee Michele L. Novel proteins and nucleic acids encoding same

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
COLUCCI M ET AL.: "Deficiency of Thrombin Activatable Fibrinolysis Inhibitor in Cirrhosis Is Associated With Increased Plasma Fibrinolysis", HEPATOLOGY, vol. 38, no. 1, July 2003 (2003-07-01), pages 230 - 237, XP008053521, ISSN: 0270-9139 *
LAETHEM R M ET AL: "Expression and characterization of human pancreatic preprocarboxypeptidase A1 and preprocarboxypeptidase A2", ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, NEW YORK, US, US, vol. 332, no. 1, 1 August 1996 (1996-08-01), pages 8 - 18, XP002104020, ISSN: 0003-9861 *
REZNIK SE & FRICKER LD: "Carboxypeptidases from A to Z: implications in embryonic development and Wnt binding", CMLS CELLULAR AND MOLECULAR LIFE SCIENCES, vol. 58, no. 12-13, November 2001 (2001-11-01), pages 1790 - 1804, XP002347828, ISSN: 1420-682X *

Also Published As

Publication number Publication date
WO2006010499A2 (en) 2006-02-02

Similar Documents

Publication Publication Date Title
WO2006027147A3 (en) Diagnostics and therapeutics for diseases associated with adrenomedullin receptor (amdr)
WO2005093092A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 44 (gpr44)
WO2004104216A3 (en) Diagnostics and therapeutics for diseases associated with dipeptidylpeptidase iv (dpp4)
WO2005106012A3 (en) Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 1 (dpp1)
WO2006010517A3 (en) Diagnostics and therapeutics for diseases associated with fibroblast activation protein (fap)
WO2005114207A3 (en) Diagnostics and therapeutics for diseases associated with aminopeptidase n (anpep)
WO2005103684A3 (en) Diagnostics and therapeutics for diseases associated with cx3c chemokine receptor 1 (cx3cr1)
WO2005106491A3 (en) Diagnostics and therapeutics for diseases associated with serum/glucocorticoid regulated kinase 1 (sgk1)
WO2006021343A3 (en) Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine receptor 3a (5-ht3a)
WO2005076007A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor p2y12 (p2y12)
WO2006010514A3 (en) Diagnostics and therapeutics for diseases associated with dual specificity mitogen-activated protein kinase kinase 5 (map2k5)
WO2005113786A3 (en) Diagnostics and therapeutics for diseases associated with chymase (cma1)
WO2005090994A3 (en) Diagnostics and therapeutics for diseases associated with protein kinase, cgmp-dependent, type i (prkg1)
WO2005093091A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 26 (gpr26)
WO2005073729A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor p2y11 (p2y11)
WO2005075983A3 (en) Diagnostics and therapeutics for diseases associated with human nuclear receptor nr4a3 (nr4a3)
WO2005085469A3 (en) Diagnostics and therapeutics for diseases associated with rho-associated protein kinase 1 (rock1)
WO2006010499A3 (en) Diagnostics and therapeutics for diseases associated with carboxypeptidase a2 (cpa2)
WO2005106486A3 (en) Diagnostic and therapeutics for diseases associated with dipeptidyl-peptidase 3(dpp3)
WO2006013013A3 (en) Diagnostics and therapeutics for diseases associated with protective protein for beta-galactosidase (ppgb)
WO2005095631A3 (en) Diagnostics and therapeutics for diseases associated with mixed lineage kinase 4 alpha (mlk4 alpha)
WO2006013012A3 (en) Diagnostics and therapeutics for diseases associated with napsin 1 (nap1)
WO2005114209A3 (en) Diagnostics and therapeutics for diseases associated with g protein-dependent receptor kinase 2 (grk2)
WO2005026719A3 (en) Diagnostics and therapeutics for diseases associated with transporter slc22a3 (slc22a3)
WO2006013015A3 (en) Diagnostics and therapeutics for diseases associated with marapsin (mpn)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase